Stock Research: Astellas Pharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Astellas Pharma

TSE:4503 JP3942400007
73
  • Value
    76
  • Growth
    96
  • Safety
    Safety
    10
  • Combined
    76
  • Sentiment
    56
  • 360° View
    360° View
    73
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Astellas Pharma Inc. is a Japan-based pharmaceutical company focused on the research, development, manufacture, and sale of pharmaceutical products. The company operates in the pharmaceutical industry, with products including XTANDI, BETANIS, and MIRABETRIC. Astellas Pharma Inc. primarily operates in Japan. In the last fiscal year, the company had a market cap of $17,488 million, profits of $10,424 million, and revenue of $12,753 million, with 13,643 employees.

more
Index
TOPIX 100
Nikkei 225
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 8-Jan-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 70 66 67
Growth
96 49 19 89
Safety
Safety
10 10 39 39
Sentiment
56 16 6 14
360° View
360° View
73 21 12 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
35 30 50 65
Opinions Change
62 23 15 50
Pro Holdings
n/a 40 16 18
Market Pulse
41 26 9 17
Sentiment
56 16 6 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 70 66 67
Growth
96 49 19 89
Safety Safety
10 10 39 39
Combined
76 35 33 76
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
61 74 59 50
Price vs. Earnings (P/E)
66 42 58 80
Price vs. Book (P/B)
33 41 45 53
Dividend Yield
96 96 91 92
Value
76 70 66 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
35 18 58 47
Profit Growth
90 67 55 79
Capital Growth
72 71 4 54
Stock Returns
96 42 27 85
Growth
96 49 19 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
21 17 59 48
Refinancing
4 4 7 21
Liquidity
53 34 72 72
Safety Safety
10 10 39 39

Similar Stocks

Discover high‑ranked alternatives to Astellas Pharma and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Alfresa Holdings

TSE:2784
Country: Japan
Industry: Health Care Distributors
Size: Large
Full Stock Analysis

Sankyu

TSE:9065
Country: Japan
Industry: Trucking
Size: Medium
Full Stock Analysis

Kumagai Gumi

TSE:1861
Country: Japan
Industry: Construction & Engineering
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: